133 related articles for article (PubMed ID: 15994388)
1. Bronchodilator response in the lung health study over 11 yrs.
Anthonisen NR; Lindgren PG; Tashkin DP; Kanner RE; Scanlon PD; Connett JE;
Eur Respir J; 2005 Jul; 26(1):45-51. PubMed ID: 15994388
[TBL] [Abstract][Full Text] [Related]
2. Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Dutch Study Group.
Maesen FP; Smeets JJ; Sledsens TJ; Wald FD; Cornelissen PJ
Eur Respir J; 1995 Sep; 8(9):1506-13. PubMed ID: 8575576
[TBL] [Abstract][Full Text] [Related]
3. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study.
Anthonisen NR; Connett JE; Kiley JP; Altose MD; Bailey WC; Buist AS; Conway WA; Enright PL; Kanner RE; O'Hara P
JAMA; 1994 Nov; 272(19):1497-505. PubMed ID: 7966841
[TBL] [Abstract][Full Text] [Related]
4. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study.
Scanlon PD; Connett JE; Waller LA; Altose MD; Bailey WC; Buist AS; Tashkin DP;
Am J Respir Crit Care Med; 2000 Feb; 161(2 Pt 1):381-90. PubMed ID: 10673175
[TBL] [Abstract][Full Text] [Related]
5. A double-blind crossover study comparing the safety and efficacy of three weeks of Flu/Sal 250/50 bid plus albuterol 180 ug prn q4 hours to Flu/Sal 250/50 bid plus albuterol/Ipratropium bromide 2 puffs prn q4 hours in patients with chronic obstructive pulmonary disease.
Balkissoon R; Make B
COPD; 2008 Aug; 5(4):221-7. PubMed ID: 18671147
[TBL] [Abstract][Full Text] [Related]
6. Does the mode of inhalation affect the bronchodilator response in patients with severe COPD?
Eiser NM; Phillips C; Wooler PA
Respir Med; 2001 Jun; 95(6):476-83. PubMed ID: 11421505
[TBL] [Abstract][Full Text] [Related]
7. Bronchodilator responsiveness in patients with COPD.
Tashkin DP; Celli B; Decramer M; Liu D; Burkhart D; Cassino C; Kesten S
Eur Respir J; 2008 Apr; 31(4):742-50. PubMed ID: 18256071
[TBL] [Abstract][Full Text] [Related]
8. Short-term effects of inhalative tiotropium/formoterol/budenoside versus tiotropium/formoterol in patients with newly diagnosed chronic obstructive pulmonary disease requiring surgery for lung cancer: a prospective randomized trial.
Bölükbas S; Eberlein M; Eckhoff J; Schirren J
Eur J Cardiothorac Surg; 2011 Jun; 39(6):995-1000. PubMed ID: 20970351
[TBL] [Abstract][Full Text] [Related]
9. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease.
Pauwels RA; Löfdahl CG; Laitinen LA; Schouten JP; Postma DS; Pride NB; Ohlsson SV
N Engl J Med; 1999 Jun; 340(25):1948-53. PubMed ID: 10379018
[TBL] [Abstract][Full Text] [Related]
10. Airways hyperresponsiveness, bronchodilator response, allergy and smoking predict improvement in FEV1 during long-term inhaled corticosteroid treatment. Dutch CNSLD Study Group.
Kerstjens HA; Overbeek SE; Schouten JP; Brand PL; Postma DS
Eur Respir J; 1993 Jun; 6(6):868-76. PubMed ID: 8339808
[TBL] [Abstract][Full Text] [Related]
11. Smoking reduction and the rate of decline in FEV(1): results from the Lung Health Study.
Simmons MS; Connett JE; Nides MA; Lindgren PG; Kleerup EC; Murray RP; Bjornson WM; Tashkin DP
Eur Respir J; 2005 Jun; 25(6):1011-7. PubMed ID: 15929955
[TBL] [Abstract][Full Text] [Related]
12. Acute bronchodilator responses decline progressively over 4 years in patients with moderate to very severe COPD.
Tashkin DP; Li N; Kleerup EC; Halpin D; Celli B; Decramer M; Elashoff R
Respir Res; 2014 Aug; 15(1):102. PubMed ID: 25175805
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.
Kerwin EM; Gotfried MH; Lawrence D; Lassen C; Kramer B
Clin Ther; 2011 Dec; 33(12):1974-84. PubMed ID: 22177371
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of the long-acting muscarinic antagonist GSK233705 delivered once daily in patients with COPD.
Bateman E; Feldman G; Kilbride S; Brooks J; Mehta R; Harris S; Maden C; Crater G
Clin Respir J; 2012 Oct; 6(4):248-57. PubMed ID: 22329914
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of ipratropium bromide/albuterol delivered via Respimat inhaler versus MDI.
Zuwallack R; De Salvo MC; Kaelin T; Bateman ED; Park CS; Abrahams R; Fakih F; Sachs P; Pudi K; Zhao Y; Wood CC;
Respir Med; 2010 Aug; 104(8):1179-88. PubMed ID: 20172704
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of acute bronchodilator reversibility in patients with symptoms of GOLD stage I COPD.
O'Donnell DE; Laveneziana P; Ora J; Webb KA; Lam YM; Ofir D
Thorax; 2009 Mar; 64(3):216-23. PubMed ID: 19052054
[TBL] [Abstract][Full Text] [Related]
17. Bronchodilator response in chronic obstructive pulmonary disease.
Anthonisen NR; Wright EC
Am Rev Respir Dis; 1986 May; 133(5):814-9. PubMed ID: 3706890
[TBL] [Abstract][Full Text] [Related]
18. The 6-min walking distance: long-term follow up in patients with COPD.
Casanova C; Cote CG; Marin JM; de Torres JP; Aguirre-Jaime A; Mendez R; Dordelly L; Celli BR
Eur Respir J; 2007 Mar; 29(3):535-40. PubMed ID: 17107991
[TBL] [Abstract][Full Text] [Related]
19. Dry powder ipratropium bromide is as safe and effective as metered-dose inhaler formulation: a cumulative dose-response study in chronic obstructive pulmonary disease patients.
Cuvelier A; Muir JF; Benhamou D; Weitzenblum E; Zuck P; Delacenserie R; Taytard A; Iacono P
Respir Care; 2002 Feb; 47(2):159-66. PubMed ID: 11812272
[TBL] [Abstract][Full Text] [Related]
20. Using post-bronchodilator FEV₁ is better than pre-bronchodilator FEV₁ in evaluation of COPD severity.
Chen CZ; Ou CY; Wang WL; Lee CH; Lin CC; Chang HY; Hsiue TR
COPD; 2012 Jun; 9(3):276-80. PubMed ID: 22360379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
